Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 11Breast Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Carcinoma, Merkel Cell 2Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Advanced Non CNS Tumors 1Adenocarcinoma 1

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1nazartinib 1canakinumab 1Therapeutics 1Telomerase 1Radiation, Ionizing 1Pemetrexed 1Paclitaxel 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Ductal × talimogene laherparepvec × Clear all
NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 12 charts
Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡